You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for BAY 876
BAY 876 is a potent and selective GLUT1 inhibitor (IC50 = 2 nM) that displays selectivity for GLUT1 over GLUT2/3/4 (IC50 values are 10.8, 1.67 and 0.29 μM, respectively). BAY 876 induces cell death in hypoxic conditions in vitro and inhibits glucose uptake by Hela-MaTu cells. In ovarian cancer, BAY 876 reduces glycolysis rates and ATP production and inhibits proliferation in vitro and in vivo. This compound is cell permeable and orally bioavailable.
External Portal Information for BAY 876
The Chemical Probes pages of the Structural Genomics Consortium website are a portal that offers independent guidance on the selection and/or application of small molecules for research. The use of BAY 876 is reviewed.
Technical Data for BAY 876
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for BAY 876
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for BAY 876
The following data is based on the product molecular weight 496.42. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.01 mL||10.07 mL||20.14 mL|
|5 mM||0.4 mL||2.01 mL||4.03 mL|
|10 mM||0.2 mL||1.01 mL||2.01 mL|
|50 mM||0.04 mL||0.2 mL||0.4 mL|
References for BAY 876
References are publications that support the biological activity of the product.
Siebeneicher et al (2016) Identification and optimization of the first highly selective GLUT1 inhibitor BAY-876. ChemMedChem. 11 2261 PMID: 27552707
Ma et al (2018) Ovarian cancer relies on glucose transporter 1 to fuel glycolysis and growth: anti-tumor activity of BAY-876. Cancers (Basel) 11 33 PMID: 30602670
If you know of a relevant reference for BAY 876, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: BAY 876, BAY 876 supplier, BAY876, potent, selective, GLUT1, inhibitors, inhibits, cell, permeable, orally, bioavailable, Glucose, Transporters, 6199, Tocris Bioscience
2 Citations for BAY 876
Citations are publications that use Tocris products. Selected citations for BAY 876 include:
Jessica E et al (2022) Prolonged culturing of iPSC-derived brain endothelial-like cells is associated with quiescence, downregulation of glycolysis, and resistance to disruption by an Alzheimer's brain milieu. Fluids Barriers CNS 19 10 PMID: 35123529
Ole et al (2022) YAP1 and PRDM14 converge to promote cell survival and tumorigenesis. Dev Cell 57 212-227.e8 PMID: 34990589
Do you know of a great paper that uses BAY 876 from Tocris? Please let us know.
Reviews for BAY 876
There are currently no reviews for this product. Be the first to review BAY 876 and earn rewards!
Have you used BAY 876?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Cancer Metabolism Research Product GuideNew
This product guide reviews some of the main areas in cancer metabolism research and lists around 150 products that can be used to investigate metabolic pathways in cancer including:
- Tricarboxylic Acid Cycle
- 1C Metabolism and Nucleic Acid Synthesis
- Drivers of Metabolic Reprogramming
- pH and Redox Balance
Cancer Metabolism Poster
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.